Concourse Financial Group Securities, Inc. Nektar Therapeutics Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding NKTR
# of Institutions
140Shares Held
134MCall Options Held
32.8KPut Options Held
55.5K-
Deep Track Capital, LP Greenwich, CT17.9MShares$24.5 Million0.73% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$20.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$17.8 Million0.0% of portfolio
-
Samlyn Capital, LLC New York, NY9.46MShares$13 Million0.21% of portfolio
-
Eventide Asset Management, LLC Boston, MA7.53MShares$10.3 Million0.16% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $257M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...